Vivian Chin, M.D., Marisa Censani, M.D., Shulamit Lerner, M.D., Rushika Conroy, M.D., Sharon Oberfield, M.D., Donald McMahon, M.S., Jeffrey Zitsman, M.D., Ilene Fennoy, M.D.
Volume 101, Issue 4, Pages 1142-1148
To describe gonadal dysfunction and evaluate polycystic ovary syndrome (PCOS) and its association with metabolic syndrome (MeS) among girls in a morbidly obese adolescent population.
In a cross-sectional study of 174 girls, height, weight, waist circumference, Tanner stage, reproductive hormones, carbohydrate and lipid markers, drug use, and menstrual history were obtained at baseline. Exclusion criteria were menarcheal age <2 years, hormonal contraceptive or metformin use, Tanner stage <4, and incomplete data on PCOS or MeS classification. Setting:
University medical center outpatient clinic.
Ninety-eight girls ages 13–19.6 years, Tanner 5, average body mass index of 46.6 kg/m2, menarche at 11.4 years, and average menarcheal age of 5 years.
Main Outcome Measure(s):
Polycystic ovary syndrome and MeS.
Ninety-eight girls were divided into four groups: PCOS by National Institutes of Health criteria (PCOSN, n = 24), irregular menses only (n = 25), elevated T (≥55 ng/dL) only (n = 6), and obese controls (n = 43). Metabolic syndrome by modified Cook criteria affected 32 girls or 33% overall: 6 of 24 PCOSN, 7 of 25 irregular menses only, 4 of 6 elevated T only, and 15 of 43 obese controls. Polycystic ovary syndrome by National Institutes of Health criteria and its individual components were not associated with MeS after adjusting for body mass index.
Unlike obese adults, PCOSN and its individual components were not associated with MeS in the untreated morbidly obese adolescent population.
Read the full text at: http://www.fertstert.org/article/S0015-0282(13)03482-1/fulltext